[AFMD] Affimed N.V.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.85 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AFMD

Refresh chart

Strongest Trends Summary For AFMD

AFMD is in the medium-term down -18% below S&P in 2 months and down -33% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company?s product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.9 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-222.01% ROE13.62% ROI
Current Ratio0.26 Quick Ratio0.26 Long Term Debt/Equity Debt Ratio-0.19
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-40 K Cash From Operating Activities-3.92 M Gross Profit
Net Profit-1.48 M Operating Profit-2 M Total Assets39.29 M Total Current Assets38.29 M
Total Current Liabilities4.13 M Total Debt4.51 M Total Liabilities8.64 M Total Revenue2.54 M
Technical Data
High 52 week4.67 Low 52 week2.6 Last close2.93 Last change9.74%
RSI33.78 Average true range0.18 Beta1.46 Volume378.6 K
Simple moving average 20 days-3.67% Simple moving average 50 days-0.26% Simple moving average 200 days-10.6%
Performance Data
Performance Week7.72% Performance Month-13.06% Performance Quart-3.62% Performance Half-18.16%
Performance Year-13.31% Performance Year-to-date-5.79% Volatility daily4.2% Volatility weekly9.39%
Volatility monthly19.24% Volatility yearly66.64% Relative Volume414.03% Average Volume539.35 K
New High New Low

News

2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

2019-11-14 06:30:00 | Affimed to Present at the Jefferies 2019 London Healthcare Conference

2019-11-14 06:30:00 | Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

2019-11-13 16:10:00 | Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

2019-11-08 08:14:09 | The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

2019-11-08 06:30:00 | Affimed Announces Pricing of Public Offering of Common Shares

2019-11-07 16:11:49 | Affimed Announces Proposed Public Offering of Common Shares

2019-11-07 16:01:00 | Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

2019-11-07 16:01:00 | Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

2019-10-30 10:33:02 | Affimed N.V. AFMD May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2019-10-19 08:23:22 | Imagine Owning Affimed NASDAQ:AFMD And Wondering If The 35% Share Price Slide Is Justified

2019-10-15 06:30:00 | Affimed Reports Progress on Key Clinical Development Programs

2019-09-04 11:52:32 | Is Affimed NASDAQ:AFMD Using Debt Sensibly?

2019-08-28 05:00:00 | Affimed to Participate in Investor Conferences in September

2019-08-09 19:45:01 | Affimed N.V. AFMD Q2 2019 Earnings Call Transcript

2019-08-07 19:17:06 | Edited Transcript of AFMD earnings conference call or presentation 7-Aug-19 12:30pm GMT

2019-08-07 09:05:01 | Affimed N.V. AFMD Reports Q2 Loss, Misses Revenue Estimates

2019-08-07 07:30:00 | Affimed Reports Second Quarter 2019 Financial and Operational Results

2019-08-06 14:16:34 | Earnings Outlook For Affimed

2019-07-31 05:00:00 | Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

2019-07-18 13:03:32 | Is Affimed N.V.'s NASDAQ:AFMD CEO Salary Justified?

2019-07-02 09:00:01 | All You Need to Know About Affimed N.V. AFMD Rating Upgrade to Buy

2019-07-01 05:00:00 | Affimed Added to the Russell 2000®, 3000® and Microcap Indexes

2019-06-24 05:00:00 | Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019

2019-06-15 12:38:28 | The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

2019-06-12 05:30:00 | Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland

2019-06-04 16:01:00 | Affimed Announces Annual General Meeting of Shareholders

2019-06-03 05:00:00 | Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology

2019-05-29 05:00:00 | Affimed to Present at the Jefferies 2019 Healthcare Conference

2019-05-23 14:25:06 | Affimed AFMD Earnings and Sales Exceed Estimates in Q1

2019-05-22 15:44:58 | Edited Transcript of AFMD earnings conference call or presentation 22-May-19 12:30pm GMT

2019-05-22 15:23:14 | Affimed N.V. AFMD Q1 2019 Earnings Call Transcript

2019-05-22 08:45:12 | Affirmed Therapeutics AFMD Beats Q1 Earnings and Revenue Estimates

2019-05-22 07:58:00 | Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10%

2019-05-22 07:30:00 | Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress

2019-05-21 14:16:18 | Affimed Q1 Earnings Preview

2019-05-16 05:00:00 | Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019

2019-05-14 10:30:02 | Affirmed Therapeutics AFMD May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-05-13 09:17:01 | What's in Store for Affimed AFMD This Earnings Season?

2019-04-30 09:00:01 | Affirmed Therapeutics AFMD Moves to Buy: Rationale Behind the Upgrade

2019-04-27 09:16:37 | If You Had Bought Affimed NASDAQ:AFMD Shares A Year Ago You'd Have Made 62%

2019-04-17 16:05:00 | Affimed Provides Regulatory Update on AFM11 Clinical Program

2019-04-09 08:48:12 | Implied Volatility Surging for Affimed AFMD Stock Options

2019-04-01 08:00:00 | Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research AACR 2019 Annual Meeting

2019-03-27 14:26:08 | Edited Transcript of AFMD earnings conference call or presentation 27-Mar-19 12:30pm GMT

2019-03-27 13:49:31 | Affimed N.V. AFMD Q4 2018 Earnings Conference Call Transcript

2019-03-27 07:30:00 | Affimed Reports 2018 Financial Results and Operational Progress

2019-03-20 05:00:00 | Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

2019-03-19 07:40:42 | The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

2019-03-19 05:00:00 | Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity